A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients.

Trial Profile

A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2019.
    • 24 Mar 2015 Planned End Date changed from 1 Aug 2015 to 1 May 2016 as reported by ClinicalTrials.gov
    • 10 Dec 2013 Status changed from recruiting to active, no longer recruiting, according to abstract presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top